Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia.
Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia.
复制标题
DOI：
10.1158/1535-7163.mct-17-0099
复制
发表时间：
2017-07
影响因子：
5.7
通讯作者：
Kelley MR
中科院分区：
文献类型：
--
作者：
Ding J;Fishel ML;Reed AM;McAdams E;Czader MB;Cardoso AA;Kelley MR
儿童急性淋巴细胞白血病（ALL）的特征越来越多，导致了多个分子靶点的鉴定，但尚未转化为更有效的靶向治疗，特别是对于高危复发性T细胞ALL。为了寻找控制T-ALL中多个信号通路的主调节因子，我们研究了多功能蛋白质氧化还原因子-1（Ref-1/APE 1），其通过对白血病中重要的转录因子施加氧化还原调节控制而充当信号“节点”。白血病患者的转录组数据库显示Ref-1和Ref-1/SET相互作用组的其他基因在T-ALL中的表达增加。验证研究表明，Ref-1在高风险白血病T细胞中表达，包括在患者活检中。Ref-1氧化还原功能在白血病T细胞中具有活性，调节Ref-1靶NF-κB，并被氧化还原选择性Ref-1抑制剂E3330抑制。Ref-1的表达不受Notch信号转导的调节，但受糖皮质激素治疗的上调。在功能研究中，E3330破坏了Ref-1的氧化还原活性，并导致白血病细胞活力的显著抑制，包括代表不同基因型和风险组的T-ALL细胞系。在ALL患者的原代细胞、复发和糖皮质激素耐药T-ALL细胞以及Notch诱导白血病小鼠模型的细胞中观察到有效的白血病细胞抑制。Ref-1氧化还原抑制触发白血病细胞凋亡和下调由Ref-1靶标调节的存活基因。这项工作首次将Ref-1鉴定为T-ALL中的新型分子效应子，并证明Ref-1氧化还原抑制导致对白血病T细胞（包括复发性T-ALL）的有效抑制。这些数据也支持E3330作为白血病的特异性Ref-1小分子抑制剂。
The increasing characterization of childhood acute lymphoblastic leukemia (ALL) has led to the identification of multiple molecular targets, but have yet to translate into more effective targeted therapies, particularly for high-risk, relapsed T-cell ALL. Searching for master regulators controlling multiple signaling pathways in T-ALL, we investigated the multi-functional protein redox factor-1 (Ref-1/APE1), which acts as a signaling “node” by exerting redox regulatory control of transcription factors important in leukemia. Leukemia patients’ transcriptome databases showed increased expression in T-ALL of Ref-1 and other genes of the Ref-1/SET interactome. Validation studies demonstrated that Ref-1 is expressed in high-risk leukemia T-cells, including in patient biopsies. Ref-1 redox function is active in leukemia T-cells, regulating the Ref-1 target NF-κB, and inhibited by the redox-selective Ref-1 inhibitor E3330. Ref-1 expression is not regulated by Notch signaling, but is upregulated by glucocorticoid treatment. E3330 disrupted Ref-1 redox activity in functional studies and resulted in marked inhibition of leukemia cell viability, including T-ALL lines representing different genotypes and risk groups. Potent leukemia cell inhibition was seen in primary cells from ALL patients, relapsed and glucocorticoid-resistant T-ALL cells, and cells from a murine model of Notch-induced leukemia. Ref-1 redox inhibition triggered leukemia cell apoptosis and down-regulation of survival genes regulated by Ref-1 targets. For the first time, this work identifies Ref-1 as a novel molecular effector in T-ALL and demonstrates that Ref-1 redox inhibition results in potent inhibition of leukemia T-cells, including relapsed T-ALL. These data also support E3330 as a specific Ref-1 small molecule inhibitor for leukemia.